<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833610</url>
  </required_header>
  <id_info>
    <org_study_id>15-571</org_study_id>
    <nct_id>NCT02833610</nct_id>
  </id_info>
  <brief_title>A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency</brief_title>
  <official_title>A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying a possible therapy as a possible treatment for the&#xD;
      consequences of Multiple Myeloma with renal insufficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase II clinical trial. This study will assess the safety and&#xD;
      tolerability of denosumab in Multiple Myeloma participants, by studying drug interactions&#xD;
      with different parts of the body.&#xD;
&#xD;
      The FDA (the U.S. Food and Drug Administration) has not approved Denosumab for this specific&#xD;
      disease but it has been approved denosumab for use in other cancers to treat cancer-related&#xD;
      bone disease such as prostate and breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change Of sCTX Levels</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change In Bone Mineral Density</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change In uNTX Levels</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Incidence Of Hypocalcemia</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Incidence Of Occurrence Of Documented SRE At 12 Months</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Incidence Of Adverse Events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change In Bone Turnover Markers</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Denosumab Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered Denosumab Q4W at a pre-determine dose for 12 cycles. Denosumab Q4W is administered by subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab Q4W</intervention_name>
    <arm_group_label>Denosumab Injection</arm_group_label>
    <other_name>Xgeva</other_name>
    <other_name>Prolia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic MM as defined by IMWG requiring anti-myeloma therapy.&#xD;
&#xD;
               -  Monoclonal plasma cells in the bone marrow greater than or equal to 10% and/or&#xD;
                  presence of a biopsy-proven plasmacytoma&#xD;
&#xD;
               -  Monoclonal protein present in the serum and/or urine&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 mL/min, not eligible for bisphosphonate. Estimated&#xD;
             glomerular filtration rate will be calculated using Cockcroft-Gault equation.&#xD;
&#xD;
          -  Serum calcium or albumin-adjusted serum calcium ≥ 2.1 mmol/L (8.4 mg/dL) and ≤ 2.9&#xD;
             mmol/L (11.5 mg/dL) (Reference range 8.5-10.8 mg/dL)&#xD;
&#xD;
          -  Able to tolerate daily supplementation of calcium and vitamin D&#xD;
&#xD;
          -  Vitamin D level ≥ 30 ng/mL after repletion&#xD;
&#xD;
          -  Participants must have normal organ as defined below:&#xD;
&#xD;
               -  Total bilirubin ≤ 2.0 x ULN&#xD;
&#xD;
               -  AST(SGOT) ≤2.5 × institutional upper limit of normal&#xD;
&#xD;
               -  ALT(SGPT) ≤2.5 × institutional upper limit of normal&#xD;
&#xD;
          -  Plan to receive anti-myeloma therapies.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Life expectancy greater than 6 months&#xD;
&#xD;
          -  0-3 lines of prior anti-myeloma therapy.&#xD;
&#xD;
          -  Subjects with reproductive potential must be willing to use, in combination with&#xD;
             his/her partner, 2 highly effective methods of effective contraception or practice&#xD;
             sexual abstinence throughout the study and continue for 5 months after the study&#xD;
             duration. Subjects who are surgically sterile (e.g. history of bilateral tubal&#xD;
             ligation, hysterectomy) or whose sexual partner is sterile (e.g. history of vasectomy)&#xD;
             are not required to use additional contraceptive measures.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior administration of denosumab.&#xD;
&#xD;
          -  Active IV bisphosphonate use in the last 3 months.&#xD;
&#xD;
          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and&#xD;
             skin changes).&#xD;
&#xD;
          -  Plasma cell leukemia.&#xD;
&#xD;
          -  Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw.&#xD;
&#xD;
          -  Active dental or jaw condition which requires oral surgery, including tooth&#xD;
             extraction.&#xD;
&#xD;
          -  Non-healed dental/oral surgery, including tooth extraction.&#xD;
&#xD;
          -  Planned invasive dental procedures during the course of study.&#xD;
&#xD;
          -  Evidence of any of the following conditions per subject self-report or medical chart&#xD;
             review&#xD;
&#xD;
               -  Any prior invasive malignancy within 5 years of enrollment that may affect&#xD;
                  outcome of study&#xD;
&#xD;
               -  Any non-invasive malignancy not treated with curative intent or with known active&#xD;
                  disease within 5 years before enrollment that may affect outcome of study&#xD;
&#xD;
               -  Major surgery or significant traumatic injury occurring within 4 weeks before&#xD;
                  enrollment&#xD;
&#xD;
               -  Active infection with Hepatitis B virus or Hepatitis C virus&#xD;
&#xD;
               -  known infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
               -  Active infection requiring IV anti-infective therapy&#xD;
&#xD;
          -  Subject is pregnant or breast feeding, or planning to become pregnant within 5 months&#xD;
             after the end of treatment.&#xD;
&#xD;
          -  Female subject of child-bearing potential is not willing to use, in combination with&#xD;
             her partner, 2 methods of highly effective contraception during treatment and for 5&#xD;
             months after the end of treatment.&#xD;
&#xD;
          -  Clinically significant hypersensitivity to denosumab 120 mg.&#xD;
&#xD;
          -  Known sensitivity to any of the products to be administered during the study (e.g.&#xD;
             calcium, or vitamin D).&#xD;
&#xD;
          -  Subject is receiving or is less than 14 days since ending other experimental drug (no&#xD;
             marketing authorization for any indication).&#xD;
&#xD;
          -  Any major medical or psychiatric disorder that, in the opinion of the investigator,&#xD;
             might prevent the subject from completing the study or interfere with the&#xD;
             interpretation of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth K O'Donnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth K O'Donnell, MD</last_name>
    <phone>617-724-4000</phone>
    <email>ekodonnell@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay Nooka, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts general Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth K O'Donnell, MD</last_name>
      <phone>617-724-4000</phone>
      <email>ekodonnell@partners.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth K O'Donnel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Laubach, MD</last_name>
      <phone>617-632-4218</phone>
      <email>Jacobp_laubach@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mass General/North Shore Cancer Center</name>
      <address>
        <city>Danvers</city>
        <state>Massachusetts</state>
        <zip>01923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Yee, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newton Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Nadeem, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brea Lipe, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ehsan Malek, MD</last_name>
      <phone>216-844-8640</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elizabeth O'Donnell</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

